| Interventions |
Current interventions as of 19/12/2024: This is a multi-centre, observational cohort study with 40 centres across the United Kingdom. We will aim to recruit 1325 participants over 27 months. Patients will be identified by the gastroenterology teams and be screened against the study eligibility criteria using the patients' medical records. Eligible patients will have the study explained to them by a member of the study team and be given the Patient information sheet for further information. Patients (up to 300 patients) who are diagnosed with Crohn' disease may be asked to be part of the sub-study called CD-metaRESPONSE, which means they complete some extra questionnaires and collect additional samples. To be eligible for the study, the participant will need to be starting a biologic therapy (an injectable medication used to control inflammation in inflammatory bowel disease e.g. infliximab, adalimumab, vedolizumab or ustekinumb) or a JAK inhibitor medication (tofacitinib) as treatment for Crohn disease or ulcerative colitis. The majority of the study will be completed remotely, at participants' home. Each participant will be provided with access to the online database, REDCap, which will be used to provide informed consent, complete questionnaires and track samples. Participants will be enrolled for approximately 54 weeks, with assessments performed at baseline (prior to starting treatment), week 14 (14 weeks after starting treatment) and at week 54 (54 weeks after starting treatment). These visits should align with patients dosing regimen. The IBD-RESPONSE research team at site will be available to support and help with any questions or concerns about the study. Assessment 1 (Baseline) - (up to 6 weeks prior to starting treatment) 1. Complete questionnaires a |